title: Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.
abstract: Dual therapy with a P2Y12receptor antagonist in addition to aspirin is the antiplatelet treatment of choice in patients with acute coronary syndromes or undergoing percutaneous coronary intervention (PCI). However, available oral P2Y12antagonists have several limitations, mostly due to their pharmacological profile, which can affect outcomes in certain clinical settings. Cangrelor is an intravenous, direct-acting, potent P2Y12inhibitor with rapid onset and offset of action, which has been recently approved for clinical use in patients undergoing PCI. In clinical trials, cangrelor has demonstrated greater efficacy than clopidogrel with a favorable safety profile among PCI patients not receiving pretreatment with oral P2Y12antagonists. However, its definitive role in contemporary practice is yet to be determined. This review aims to provide a comprehensive overview of the current status of knowledge on cangrelor, focusing on its pharmacological properties, clinical development, and the potential applications of this newly available agent.
authors.affiliation: Heart Diseases Institute, Bellvitge University Hospital-IDIBELL, University of Barcelona, c/Feixa Llarga s/n, CP 08907, L'Hospitalet de Llobregat, Barcelona, Spain.
authors.forename: Ana Lucrecia
authors.initials: AL
authors.lastname: Marcano
authors.affiliation: Heart Diseases Institute, Bellvitge University Hospital-IDIBELL, University of Barcelona, c/Feixa Llarga s/n, CP 08907, L'Hospitalet de Llobregat, Barcelona, Spain. jlferreiro@bellvitgehospital.cat.
authors.forename: José Luis
authors.initials: JL
authors.lastname: Ferreiro
mesh_terms: D000249:Adenosine Monophosphate / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D006801:Humans; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D058921:Purinergic P2Y Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D058925:Receptors, Purinergic P2Y12 / Q000378:metabolism
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D000249:Adenosine Monophosphate; C117446:cangrelor
keywords: Acute coronary syndrome; Antiplatelet therapy; Cangrelor; Percutaneous coronary intervention